

TREATMENT WITH ⁹⁰Y-ZEVALIN

In a comprehensive treatment of some non-Hodgkin's lymphomas, ⁹⁰Y-Zevalin is often used in specific cases. ⁹⁰Y-Zevalin binds to the CD20 antigen found on the surface of lymphoma cells, causing the destruction of these cells. During treatment, the patient will stay twice in the hospital for a short period of time, where he or she can use a private room with a toilet, sink and shower, as well as a TV, cable and non-cable Internet, telephone, refrigerator, microwave and hair dryer.

⁹⁰Y-Zevalin is indicated for the treatment of non-Hodgkin's lymphoma, depending on the specific form of the disease and the stage of the treatment.

Contraindications for treatment include:

- pregnancy;
- breastfeeding;
- hypersensitivity to the components of the medicinal product.

Inform your doctor and research staff if:

- you are pregnant;
- you are breastfeeding;
- you have experienced claustrophobia or the fear of enclosed spaces.

Possible side effects:

- bruising and decrease in platelet, red or white cell counts;
- nausea, abdominal pain, constipation, diarrhoea, indigestion;
- weakness, fever, chills;
- hypersensitivity reactions;
- bone or muscle pain.

Preparation for treatment

During the pre-treatment consultation, you will be informed about the details of the treatment procedure, the course of treatment, the expected benefits and the possible side effects. Also, you will be given individual pre- and post-treatment guidance.

Breastfeeding should be stopped immediately before treatment.

Since pregnancy is contraindicated, a pregnancy test will be performed, if necessary, before the procedure. After treatment, avoid conceiving a child for at least six months.

Administration of treatment

On the day of treatment, the details of the procedure, the course of treatment and radiation safety requirements will be explained again, and your medical history and blood samples will be collected. You must sign a consent form before proceeding with the procedure.

Treatment is administered twice at an interval of approximately 1 week.

The first time (i.e., on the first day of treatment), an infusion of non-radioactive rituximab will be performed. The second time (i.e., on the 7th, 8th or 9th day of treatment), an infusion of non-radioactive rituximab will first be performed and, after four hours, ⁹⁰Y-Zevalin will be administered within 10 minutes.

After the procedure:

- drink plenty of fluids so that the unbound medicinal product may be cleared faster from the body;
- for a month, avoid close contact with people around you, especially infants and toddlers, as well as pregnant and breastfeeding women;
- stop breastfeeding;
- use effective contraception for at least six months to avoid conceiving a child;
- after treatment, you will receive medical follow-up;
- if necessary, you will be given additional advice on radiation safety.

For further explanations, please call 617 1221 or 617 1216 or 617 1085.

The North Estonia Medical Centre

J. Sütiste tee 19
13419 Tallinn

www.regionaalhaigla.ee
info@regionaalhaigla.ee

This leaflet was prepared by the Department of Nuclear Medicine of the North Estonia Medical Centre (2018).